LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444 | Survodutide | Phase 3 | Recruiting | Boehringer Ingelheim | 1,800 | Dec 27, 2031 | Oct 1, 2026 |
LIVERAGE™ – Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457 | Survodutide | Phase 3 | Recruiting | Boehringer Ingelheim | 1,590 | Jun 5, 2029 | Oct 1, 2026 |
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
NCT05567796 | Cagrilintide | Phase 3 | Active not recruiting | Novo Nordisk A/S | 3,400 | Oct 30, 2024 | Sep 30, 2026 |
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
NCT06606106 | Brenipatide | Phase 1 | Active not recruiting | Eli Lilly and Company | 302 | Nov 2026 | Sep 30, 2026 |
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT06603571 | Eloralintide | Phase 2 | Completed | Eli Lilly and Company | 367 | Jul 1, 2026 | Sep 29, 2026 |
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
NCT06131372 | Cagrilintide | Phase 2 | Completed | Novo Nordisk A/S | 626 | Sep 24, 2025 | Sep 24, 2026 |
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966 | Brenipatide | Phase 3 | Recruiting | Eli Lilly and Company | 1,100 | Apr 2028 | Sep 22, 2026 |
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953 | Brenipatide | Phase 3 | Recruiting | Eli Lilly and Company | 1,100 | Apr 2028 | Sep 22, 2026 |
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058 | Enicepatide (CT-388) | Phase 3 | Recruiting | Hoffmann-La Roche | 1,600 | Aug 7, 2028 | Sep 14, 2026 |
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045 | Enicepatide (CT-388) | Phase 3 | Recruiting | Hoffmann-La Roche | 2,000 | Jul 24, 2028 | Sep 14, 2026 |
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475 | Nisotirostide | Phase 2 | Recruiting | Eli Lilly and Company | 200 | May 2027 | Sep 14, 2026 |
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
NCT07670416 | Enicepatide (CT-388) | Phase 3 | Recruiting | Hoffmann-La Roche | 300 | Feb 24, 2028 | Sep 10, 2026 |
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
NCT07184086 | Cagrilintide | Phase 1 | Active not recruiting | Novo Nordisk A/S | 80 | Oct 12, 2027 | Sep 10, 2026 |
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
NCT07010432 | Cagrilintide | Phase 1 | Recruiting | Novo Nordisk A/S | 144 | May 3, 2028 | Sep 10, 2026 |
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
NCT06323161 | Cagrilintide | Phase 3 | Completed | Novo Nordisk A/S | 274 | Sep 9, 2025 | Sep 9, 2026 |
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
NCT05202353 | Survodutide | Phase 1 | Active not recruiting | Boehringer Ingelheim | 29 | Jan 6, 2027 | Sep 9, 2026 |
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants
NCT07626515 | Enicepatide (CT-388) | Phase 1 | Recruiting | Hoffmann-La Roche | 36 | May 14, 2027 | Sep 8, 2026 |
A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight
NCT07808060 | Eloralintide | Phase 1 | Not yet recruiting | Eli Lilly and Company | 34 | Jun 2027 | Sep 8, 2026 |
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
NCT07220759 | Cagrilintide | Phase 3 | Active not recruiting | Novo Nordisk A/S | 330 | May 12, 2027 | Sep 4, 2026 |
Safety and Efficacy of J147 in Acute Ischemic Stroke
NCT07430917 | J-147 | Phase 2 | Recruiting | Abrexa Pharmaceuticals, Inc. | 196 | Mar 1, 2028 | Aug 24, 2026 |
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
NCT05929066 | Retatrutide | Phase 3 | Completed | Eli Lilly and Company | 2,335 | Apr 6, 2026 | Aug 21, 2026 |
AT1001 for the Treatment of Long COVID
NCT05747534 | Larazotide | Phase 2 | Completed | Massachusetts General Hospital | 107 | Jun 18, 2026 | Aug 18, 2026 |
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
NCT06066528 | Survodutide | Phase 3 | Completed | Boehringer Ingelheim | 755 | Dec 12, 2025 | Aug 6, 2026 |
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
NCT07220642 | Cagrilintide | Phase 3 | Active not recruiting | Novo Nordisk A/S | 300 | May 11, 2027 | Aug 6, 2026 |
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756 | Brenipatide | Phase 3 | Recruiting | Eli Lilly and Company | 1,000 | Feb 2028 | Aug 6, 2026 |
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
NCT05616013 | Bimagrumab | Phase 2 | Completed | Eli Lilly and Company | 507 | May 16, 2024 | Jul 8, 2026 |
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06065540 | Cagrilintide | Phase 3 | Completed | Novo Nordisk A/S | 2,734 | Nov 19, 2025 | Jul 8, 2026 |
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
NCT07607587 | Cagrilintide | Phase 1 | Recruiting | Novo Nordisk A/S | 114 | Nov 19, 2027 | Jun 25, 2026 |
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT06230523 | Eloralintide | Phase 2 | Completed | Eli Lilly and Company | 263 | May 30, 2025 | Jun 24, 2026 |
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
NCT06628362 | Enicepatide (CT-388) | Phase 2 | Active not recruiting | Carmot Therapeutics, Inc. | 447 | May 29, 2026 | Jun 24, 2026 |
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
NCT07357415 | Retatrutide | Phase 3 | Active not recruiting | Eli Lilly and Company | 600 | Oct 2028 | Jun 9, 2026 |
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
NCT06643728 | Bimagrumab | Phase 2 | Active not recruiting | Eli Lilly and Company | 252 | Jan 16, 2026 | May 26, 2026 |
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
NCT06745284 | Survodutide | Phase 1 | Active not recruiting | Boehringer Ingelheim | 64 | Jan 8, 2027 | May 12, 2026 |
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
NCT06309992 | Survodutide | Phase 3 | Completed | Boehringer Ingelheim | 218 | Oct 9, 2025 | Apr 30, 2026 |
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
NCT06525935 | Enicepatide (CT-388) | Phase 2 | Completed | Carmot Therapeutics, Inc. | 469 | Dec 8, 2025 | Apr 17, 2026 |
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
NCT07104383 | VK2735 | Phase 3 | Active not recruiting | Viking Therapeutics, Inc. | 1,100 | Jul 1, 2027 | Apr 7, 2026 |
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity
NCT07505745 | MOTS-c | Phase 2 | Recruiting | Hudson Biotech | 120 | Feb 14, 2027 | Apr 1, 2026 |
A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems
NCT06352411 | Survodutide | Phase 1 | Completed | Boehringer Ingelheim | 42 | Sep 16, 2025 | Mar 13, 2026 |
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity
NCT06200467 | Survodutide | Phase 1 | Completed | Boehringer Ingelheim | 110 | Oct 22, 2025 | Mar 13, 2026 |
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
NCT06066515 | Survodutide | Phase 3 | Completed | Boehringer Ingelheim | 726 | Dec 2, 2025 | Mar 12, 2026 |
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
NCT06354660 | Retatrutide | Phase 3 | Completed | Eli Lilly and Company | 537 | Jan 22, 2026 | Mar 5, 2026 |
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo
NCT07437560 | Melanotan 2 | Phase 2 | Recruiting | Hudson Biotech | 60 | Feb 14, 2027 | Feb 27, 2026 |
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
NCT06131437 | Cagrilintide | Phase 3 | Completed | Novo Nordisk A/S | 809 | Dec 8, 2025 | Feb 6, 2026 |
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
NCT06445075 | Apitegromab | Phase 2 | Completed | Scholar Rock, Inc. | 102 | Mar 4, 2025 | Jan 23, 2026 |
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
NCT05156320 | Apitegromab | Phase 3 | Completed | Scholar Rock, Inc. | 188 | Dec 18, 2024 | Jan 22, 2026 |
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
NCT05931367 | Retatrutide | Phase 3 | Completed | Eli Lilly and Company | 445 | Nov 14, 2025 | Jan 21, 2026 |
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
NCT04982575 | Cagrilintide | Phase 2 | Completed | Novo Nordisk A/S | 92 | Jul 7, 2022 | Dec 23, 2025 |
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus
NCT05814107 | CT-996 | Phase 1 | Completed | Carmot Australia First Pty Ltd | 94 | Nov 7, 2025 | Nov 28, 2025 |
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
NCT05936151 | Retatrutide | Phase 2 | Completed | Eli Lilly and Company | 146 | Oct 1, 2025 | Nov 25, 2025 |
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT05016882 | Cagrilintide | Phase 2 | Completed | Novo Nordisk A/S | 698 | Dec 17, 2024 | Nov 19, 2025 |
